Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMRFree Report) by 5.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,335,712 shares of the company’s stock after acquiring an additional 278,287 shares during the period. Price T Rowe Associates Inc. MD owned 9.62% of Kymera Therapeutics worth $135,848,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC acquired a new position in Kymera Therapeutics during the fourth quarter worth $792,000. BVF Inc. IL lifted its stake in Kymera Therapeutics by 8.9% during the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock worth $131,419,000 after purchasing an additional 422,797 shares in the last quarter. Seven Eight Capital LP acquired a new position in Kymera Therapeutics during the fourth quarter worth $571,000. Dark Forest Capital Management LP lifted its stake in Kymera Therapeutics by 89.0% during the third quarter. Dark Forest Capital Management LP now owns 36,698 shares of the company’s stock worth $510,000 after purchasing an additional 17,280 shares in the last quarter. Finally, FMR LLC lifted its stake in Kymera Therapeutics by 3.9% during the third quarter. FMR LLC now owns 870,547 shares of the company’s stock worth $12,101,000 after purchasing an additional 32,335 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR traded down $1.58 during midday trading on Friday, hitting $33.29. 408,446 shares of the company’s stock traded hands, compared to its average volume of 659,301. The company has a market cap of $2.04 billion, a PE ratio of -13.40 and a beta of 2.25. The firm’s fifty day moving average price is $35.05 and its two-hundred day moving average price is $33.38. Kymera Therapeutics, Inc. has a twelve month low of $9.60 and a twelve month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. The company had revenue of $10.30 million during the quarter, compared to the consensus estimate of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The company’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.70) EPS. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.86 EPS for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the topic of a number of research reports. Truist Financial upped their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Piper Sandler upped their price objective on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 3rd. JPMorgan Chase & Co. upped their price objective on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Oppenheimer cut their price objective on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating on the stock in a research report on Friday, May 3rd. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.70.

Check Out Our Latest Research Report on KYMR

Kymera Therapeutics Profile

(Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Read More

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.